drugset / Trial / NCT04560166
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
An International, Single-Arm, Multicenter Phase 2 Trial.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2022-09-21
- Completion
- 2022-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Naxitamab | Monoclonal antibody | 2.25 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | Oral |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |